Abraxane Injectable Suspension (paclitaxel protein-bound particles (albumin-bound)) for injectable suspension
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
WARNINGS AND PRECAUTIONS
- … Patients with hepatic impairment may be at increased risk of toxicity,particularly from myelosuppression; such patients should be closely monitored for development of profound myelosuppression. ABRAXANE is not recommended in patients who have total bilirubin >5 x ULN or AST >10 x ULN. In addition, ABRAXANE is notrecommended in patients with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment (total bilirubin >1.5 x ULN and AST =10 x ULN)…
Post-Marketing Experience with ABRAXANE and other Paclitaxel Formulations
- Cardiovascular: There have been reports of congestive heart failure, left ventricular dysfunction, and atrioventricular block with ABRAXANE. Most of the individuals were previously exposed to cardiotoxic drugs, such as anthracyclines, or had underlying cardiac history.
Clinical Trial Experience in Metastatic Breast Cancer
- sepsis and neutropenic sepsis